GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Total Receivables

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Total Receivables : $0.13 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Total Receivables?

Telomir Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2024 was $0.13 Mil.


Telomir Pharmaceuticals Total Receivables Historical Data

The historical data trend for Telomir Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Total Receivables Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Total Receivables
- - 0.13

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial Premium Member Only - - 0.13 0.13 0.13

Telomir Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Telomir Pharmaceuticals Total Receivables Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines